Immunovant, Inc.
IMVT
$13.84
-$1.38-9.07%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -116.11% | -86.01% | -17.87% | -26.73% | 18.68% |
| Total Depreciation and Amortization | 70.69% | 58.93% | 50.94% | 18.52% | 18.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.03% | 17.49% | 23.16% | 26.78% | 14.42% |
| Change in Net Operating Assets | 83.32% | 162.46% | -117.06% | 232.42% | -182.35% |
| Cash from Operations | -113.15% | -47.60% | -60.86% | -7.00% | -1.52% |
| Capital Expenditure | -37.40% | -476.47% | -304.44% | -476.92% | -33.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -37.40% | -476.47% | -304.44% | -476.92% | -33.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.48% | 393.24% | -22.92% | 563.09% | 571.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -2,110.29% |
| Cash from Financing | -99.48% | 393.24% | -22.92% | 563.09% | 565.21% |
| Foreign Exchange rate Adjustments | 90.72% | 1,319.77% | 812.77% | 657.55% | -159.55% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -123.34% | -45.03% | -61.81% | 0.90% | 1,468.88% |